Iovance Biotherapeutics, Inc.
corporate_fare Company Profile
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for IOVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for IOVA spans 10-Q, 8-K, S-3ASR.
Recent high-impact activity:
- Iovance Q3: Record $121.5M Revenue, Net Loss Narrows to $22.3M, $382.3M Cash
- Iovance Posts Record $122M Q3 Revenue, 60% Gross Margin; Reiterates $410-420M FY Guidance
- Iovance Adds Precision TIL Strategy as Enriched Lung Subgroup Hits 59.1% ORR
- Iovance Slides as Phase 2 Amtagvi NSCLC Data Disappoints
- Lifileucel Hits 24.6% ORR in NSCLC; Biomarker Subgroup Reaches 59.1%
Financial Snapshot
Short Interest & Short Volume
4.17 days to coverFINRA reported short interest of 65,189,660 shares in IOVA as of the October 30, 2026 settlement, a 10.6% increase from the prior period — about 4.2 days to cover at its recent average daily volume. On November 20, 2026, 31.6% of IOVA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for IOVA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-18.
At-The-Market Offering Extension · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →